Neurocrine stock took a hit late Thursday after the biotech company issued a light 2025 outlook for its drug, Ingrezza.

CTRL+C is a monthly Teen Vogue style series where we ask our favorite creators to test out the styles of the internet's most talked-about celebrities, dissecting their most buzz-worthy looks to see if ...

Are you fed up with the daily grind, coffee-fueled mornings and endless meetings that make up the corporate rat race? Many dream of breaking free from its ...

Harvey Jones thought his Scottish Mortgage shares were heading for a bumpy ride when DeepSeek emerged last month. Then he had ...

But with KC going for a three-peat and passionate Eagles fans yearning to attend, several travel trends have emerged, as ...

Mark Zuckerberg’s Facebook, once a simple networking site built in his Harvard dorm room, has grown into Meta Platforms — a ...

Welcome to the Money blog as the Bank of England announces a cut in the base rate from 4.75% to 4.5%. That's all from our live Q&A and the Money blog today - scroll down to read expert answers on what ...

Now, Shark is taking a shot at the luxury LED skincare market with the launch of its CryoGlow face mask. The Shark CryoGlow ...

In the Find My app on your iPhone, iPad or Mac, tap the Items button to view the AirTags you've activated. On an Apple Watch, ...

Despite a volatile trading environment and cautious customer sentiment, Amazon delivered a strong 2024 performance. In Retail ...

DeepSeek device ban, Amazon’s profit engine, Mira Murati’s latest hire. Plus: iPhone SE revamp, Sprinklr layoffs, Pinterest ...